The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 01, 2024
Filed:
Jun. 24, 2022
Applicant:
Celgene Corporation, Summit, NJ (US);
Inventors:
Maria Soraya Carrancio Anton, San Diego, CA (US);
Tonia J. Buchholz, Moss Beach, CA (US);
Antonia Lopez-Girona, San Diego, CA (US);
Rama Krishna Narla, San Diego, CA (US);
Michael Pourdehnad, San Francisco, CA (US);
Assignee:
Celgene Corporation, Summit, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C07D 413/14 (2013.01); A61P 35/00 (2018.01); C07K 16/2887 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01);
Abstract
Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.